Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancers
1 trial -
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
The First People's Hospital of Lianyungang
Breast Cancers
1 trial -
Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
The University of Hong Kong
Recurrent Ovarian Carcinoma
1 trial -
Peanuts
United Therapeutics Europe Ltd
Prediabetes
1 trial -
Phase 1 Wonderlab Product
Chongqing Precision Biotech Co., Ltd
Diabetes
1 trial -
Power Line Program
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Metabolic Health
1 trial -
Pregabalin
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Abuse
1 trial -
Pregabalin capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Fibromyalgia
1 trial -
Probiotics
Sun Yat-sen University
Cardiometabolic Risk Factors
1 trial -
Progesterone
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Abuse
2 trials -
Pueraria lobata radix
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
QiMeiYan Probiotics
Chongqing Precision Biotech Co., Ltd
IBS - Irritable Bowel Syndrome
1 trial -
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Hospital Authority, Hong Kong
Hemodynamic Instability
1 trial -
Rabeprazole
Universal Integrated
Peptic Ulcer Disease
1 trial -
Rabeprazole 20mg twice daily
Hospital Authority, Hong Kong
Chest Pain
1 trial -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Rehabilitation Therapy as part of Standard of Care (Control)
BRIGHT MINDS BIOSCIENCES INC.
Acute Stroke
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenic Purpura
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
Secukinumab 300 MG; Tofacitinib 11mg
The First People's Hospital of Lianyungang
Hidradenitis Suppurativa
1 trial -
Single dose of ibuprofen (800 mg tablet)
BRIGHT MINDS BIOSCIENCES INC.
Human Gastrointestinal Physiology Data
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources